Breaking News Instant updates and real-time market news.

ABMD

Abiomed

$333.74

3.69 (1.12%)

07:45
01/22/19
01/22
07:45
01/22/19
07:45

Abiomed price target lowered to $400 from $450 at BTIG

BTIG analyst Sean Lavin lowered his price target on Abiomed to $400 as part of his broader research note previewing earnings for the Medical Technology sector to bring the company's target valuation closer in line with its peers. The analyst believes that given the premium valuations in the sector, many companies that are yet to offer results have little room for error. However, Lavin also sees Abiomed's "above-average revenue growth and gross margin" justifying its premium valuation and maintains his Buy rating on the shares.

  • 27

    Jan

  • 31

    Jan

ABMD Abiomed
$333.74

3.69 (1.12%)

01/07/19
PIPR
01/07/19
NO CHANGE
Target $480
PIPR
Overweight
Abiomed Q3 beat shows momentum remains strong, says Piper Jaffray
Abiomed this morning reported preliminary fiscal Q3 revenue above the Street estimate and raised its 2019 revenue guidance to $780M, above the prior range of $765M-$770M, Piper Jaffray analyst Matt O'Brien tells investors in a research note. The analyst sees the results as evidence the company's momentum in is core business remains strong. He believes the stock should continue to be owned as he expects the shares to "continue lifting meaningfully this year." O'Brien keeps an Overweight rating on Abiomed with a $480 price target.
11/12/18
SPHN
11/12/18
NO CHANGE
Target $415
SPHN
Overweight
Abiomed STEMI DTU results look 'very promising,' says Stephens
After Abiomed presented data demonstrating that unloading the left ventricle with Impella CP for 30 minutes prior to reperfusion in STEMI patients without cardiogenic shock is safe and feasible, Stephens analyst Chris Cooley called the study results "very promising" and sees the potential for a pivotal trial to increase the company's addressable market by about 250,000 patients annually. He views the pullback in Abiomed shares reflecting broader market trends impacting higher-growth and multiple stocks, rather than disappointment with the data, Cooley tells investors. He reiterates an Overweight rating and $415 price target on Abiomed shares.
11/12/18
PIPR
11/12/18
NO CHANGE
Target $480
PIPR
Overweight
Piper Jaffray would buy Abiomed amid 'surprising' post-call pullback
Piper Jaffray analyst Matt O'Brien noted that Abiomed hosted a conference call on its STEMI safety and feasibility study that was released yesterday and he is "surprised" by the stock's pullback following the call. This was only supposed to be a feasibility study with a small number of patients and Impella was used in both arms, which will not be the case in the pivotal study, O'Brien points out. Without Impella in the pivotal study, he expects a more pronounced benefit to patients with mechanical support once it is done, O'Brien added. He would be using the weakness to buy Abiomed and keeps an Overweight rating on the shares with a $480 price target.
11/11/18
PIPR
11/11/18
NO CHANGE
Target $480
PIPR
Overweight
Abiomed positive updates should push shares higher, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien notes that Abiomed announced positive results of its Door to Unload STEMI safety and feasibility study, and announced it would be conducting a pivotal trial to pursue this indication, which would be the first of its kind in STEMI and would meaningfully alter the paradigm of heart health standard of care if positive. The analyst believes that these positive updates will likely push shares higher tomorrow. O'Brien continues to view Abiomed as one of the most compelling growth names in his coverage that investors should own. The analyst reiterates an Overweight rating and $480 price target on the shares.

TODAY'S FREE FLY STORIES

03:45
03/21/19
03/21
03:45
03/21/19
03:45
General news
FX Update: The dollar has tumbled »

FX Update: The dollar has…

02:55
03/21/19
03/21
02:55
03/21/19
02:55
General news
Asian Market Wrap: »

Asian Market Wrap: The…

IFF

International Flavors

$122.54

-0.98 (-0.79%)

21:34
03/20/19
03/20
21:34
03/20/19
21:34
Upgrade
International Flavors rating change at Goldman Sachs »

International Flavors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

QRVO

Qorvo

$69.15

-0.93 (-1.33%)

21:34
03/20/19
03/20
21:34
03/20/19
21:34
Upgrade
Qorvo rating change at Goldman Sachs »

Qorvo upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

ATI

Allegheny Technologies

$26.02

0.065 (0.25%)

21:34
03/20/19
03/20
21:34
03/20/19
21:34
Upgrade
Allegheny Technologies rating change at Goldman Sachs »

Allegheny Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INAP

Internap

$4.98

0.17 (3.53%)

21:33
03/20/19
03/20
21:33
03/20/19
21:33
Upgrade
Internap rating change at Wells Fargo »

Internap upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRI

Darden

$108.62

-1.79 (-1.62%)

, CAG

Conagra Brands

$22.91

0.095 (0.42%)

20:25
03/20/19
03/20
20:25
03/20/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

DRI

Darden

$108.62

-1.79 (-1.62%)

CAG

Conagra Brands

$22.91

0.095 (0.42%)

CMC

Commercial Metals

$16.06

-0.06 (-0.37%)

GIII

G-III Apparel

$35.09

-0.475 (-1.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 21

    Mar

  • 21

    Mar

  • 21

    Mar

HYMTF

Hyundai Motor

$0.00

(0.00%)

19:51
03/20/19
03/20
19:51
03/20/19
19:51
Periodicals
Hyundai shareholders to vote on Elliott Management dividend demand, Reuters says »

Hyundai Motor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVBF

CVB Financial

$21.12

-0.53 (-2.45%)

19:45
03/20/19
03/20
19:45
03/20/19
19:45
Hot Stocks
CVB Financial raises quarterly dividend to 18c from 14c per share »

The dividend will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KAMN

Kaman

$57.84

0.345 (0.60%)

19:24
03/20/19
03/20
19:24
03/20/19
19:24
Periodicals
Kaman exploring sale of distribution segment, Bloomberg says »

Kaman is looking into a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Apr

VALE

Vale

$13.49

-0.21 (-1.53%)

19:19
03/20/19
03/20
19:19
03/20/19
19:19
Hot Stocks
Vale suspends operations at Alegria mine in Mariana complex on preventive basis »

Vale S.A. informs that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

EQH

AXA Equitable

$20.84

-0.565 (-2.64%)

19:12
03/20/19
03/20
19:12
03/20/19
19:12
Syndicate
AXA Equitable 40M share Secondary priced at $20.50 »

JPMorgan, Morgan Stanley…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

OTTW

Ottawa Bancorp

$13.56

-0.14 (-1.02%)

19:02
03/20/19
03/20
19:02
03/20/19
19:02
Hot Stocks
Ottawa Bancorp declares special dividend of 35c per share »

The special dividend will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAZZ

Jazz Pharmaceuticals

$133.73

-1.74 (-1.28%)

18:57
03/20/19
03/20
18:57
03/20/19
18:57
Hot Stocks
Jazz Pharmaceuticals' Sunosi for excessive daytime sleepiness approved by FDA »

Jazz…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

AYI

Acuity Brands

$123.00

-5.53 (-4.30%)

18:52
03/20/19
03/20
18:52
03/20/19
18:52
Upgrade
Acuity Brands rating change at Goldman Sachs »

Acuity Brands upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Apr

HYAC

Haymaker Acquisition

$11.79

(0.00%)

, OSW

OneSpaWorld

$0.00

(0.00%)

18:47
03/20/19
03/20
18:47
03/20/19
18:47
Hot Stocks
OneSpaWorld says will start trading on Nasdaq March 21 »

OneSpaWorld Holdings…

HYAC

Haymaker Acquisition

$11.79

(0.00%)

OSW

OneSpaWorld

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLHR

Herman Miller

$35.07

-0.85 (-2.37%)

, MU

Micron

$40.08

-0.3 (-0.74%)

18:46
03/20/19
03/20
18:46
03/20/19
18:46
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

MLHR

Herman Miller

$35.07

-0.85 (-2.37%)

MU

Micron

$40.08

-0.3 (-0.74%)

WSM

Williams-Sonoma

$56.88

0.09 (0.16%)

SIEN

Sientra

$9.76

0.945 (10.73%)

EB

Eventbrite

$20.09

-0.72 (-3.46%)

GES

Guess

$22.10

-0.41 (-1.82%)

UNIT

Uniti Group

$10.01

0.15 (1.52%)

WEX

Wex

$184.85

-1.465 (-0.79%)

CBMG

Cellular Biomedicine

$18.26

0.38 (2.13%)

FTDR

Frontdoor

$32.10

-2.29 (-6.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 02

    Apr

  • 03

    Apr

  • 28

    May

  • 21

    Mar

  • 21

    Mar

SAGE

Sage Therapeutics

$152.62

-3.46 (-2.22%)

18:39
03/20/19
03/20
18:39
03/20/19
18:39
Hot Stocks
Sage Therapeutics CEO: Postpartum depression is a medical issue »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$174.38

-1.39 (-0.79%)

18:27
03/20/19
03/20
18:27
03/20/19
18:27
Recommendations
Nvidia analyst commentary at Tigress Financial »

Nvidia to overcome…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CURLF

Curaleaf Holdings

$0.00

(0.00%)

, CVS

CVS Health

$56.17

-0.93 (-1.63%)

18:24
03/20/19
03/20
18:24
03/20/19
18:24
Periodicals
CVS to start selling CBD products in partnership with Curaleaf, Bloomberg says »

Curaleaf (CURLF) said…

CURLF

Curaleaf Holdings

$0.00

(0.00%)

CVS

CVS Health

$56.17

-0.93 (-1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

PETQ

PetIQ

$29.87

0.91 (3.14%)

18:23
03/20/19
03/20
18:23
03/20/19
18:23
Hot Stocks
PetIQ CEO: We are totally transparent about our price model »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

T

AT&T

$30.51

-0.19 (-0.62%)

18:21
03/20/19
03/20
18:21
03/20/19
18:21
Periodicals
AT&T CEO: Huawei makes it hard for carriers to shift suppliers, Reuters says »

AT&T CEO Randall…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 24

    Apr

  • 26

    Apr

  • 07

    May

  • 20

    May

SGSOY

SGS SA

$0.00

(0.00%)

18:19
03/20/19
03/20
18:19
03/20/19
18:19
Downgrade
SGS SA rating change at Goldman Sachs »

SGS SA downgraded to Sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLX

Clorox

$155.94

-0.93 (-0.59%)

, RBGLY

Reckitt Benckiser

$0.00

(0.00%)

18:16
03/20/19
03/20
18:16
03/20/19
18:16
Hot Stocks
Clorox files false advertising lawsuit against Reckitt Benckiser »

The Clorox Company (CLX)…

CLX

Clorox

$155.94

-0.93 (-0.59%)

RBGLY

Reckitt Benckiser

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

BA

Boeing

$376.41

2.54 (0.68%)

18:09
03/20/19
03/20
18:09
03/20/19
18:09
Periodicals
Boeing pushes flight test to International Space Station to August, Reuters says »

Boeing has postponed by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 28

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.